Physician profile
John R Debanto
NPI 1033175922
$625.91
in general payments reported to CMS, 2019-2025
11 companies · $13.70 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $262 · 2023: $40.55 · 2024: $22.31 · 2025: $13.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $204.01 | 2021-2022 | |
| Redhill Biopharma INC. | $135.73 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.07 | 2021-2023 | Gattex |
| Qol Medical, LLC | $47.91 | 2022-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $35.54 | 2022 | |
| Sebela Pharmaceuticals INC. | $16.20 | 2022 | |
| Gilead Sciences, INC. | $13.88 | 2022 | |
| Genzyme Corporation | $13.70 | 2025 | |
| Intercept Pharmaceuticals, INC. | $12.95 | 2022 | |
| Organon LLC | $9.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Debanto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.